Semaglutide

Description

Semaglutide (CAS:910463-68-2) (GLP1-S), also designated NN9535, is a synthetic 31 amino acid GLP-1 receptor agonist analog supplied by AusPepLabs for laboratory and analytical research applications. Structurally modified from native GLP-1 with amino acid substitutions and a C-18 fatty acid chain that enhances albumin binding and stability, Semaglutide is one of the most extensively referenced incretin analogs in current metabolic research. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

Why Research Laboratories Select GLP1-S

Semaglutide is among the most studied GLP-1 receptor agonist analogs in current metabolic and endocrine research. Its structural modifications – including two amino acid substitutions compared to native GLP-1 and a C-18 fatty acid chain – give it enhanced stability and albumin binding properties, making it a valuable reference compound for laboratories studying sustained GLP-1 receptor activation, incretin signaling dynamics, and comparative receptor biology.

• 31 amino acid GLP-1 analog with C-18 fatty acid chain for enhanced stability in experimental settings
• Single receptor target – GLP-1R – useful for comparative studies against dual and triple agonists
• Extensively referenced in peer-reviewed literature on incretin biology and metabolic signaling
• Widely used as a reference compound in studies comparing GLP-1 class analogs
• Lyophilized format ensures stability and reproducibility across experimental runs